Postmarketing study shows comparable outcomes for patients older than 70 years.
ONCOLOGY
Fully funded by 
Content independently selected
-
R/R ATL: mogamulizumab benefit confirmed, even in the elderly -
R/R AML: phase 2 results for FLAG intensified by mitoxantrone More than 7 in 10 patients achieved complete remission.
-
Adolescent leukemia: survivors face challenges resuming school Interventions needed to help survivors readapt.
-
Study investigates bidirectional links between leukemias, SPCs Findings may assist in prognostic assessment/treatment decisions.
-
CMML: relative survival remains poor in Switzerland, U.S. Incidence expected to increase as the population ages.
-
AML: add-on eltrombopag fails to benefit ICT in phase 2 trial More serious AEs in patients receiving eltrombopag.
-
FDA approves ibrutinib+obinutuzumab for frontline CLL/SLL 77% reduction in risk for disease progression or death.
-
Pediatric high-risk ALL: (NOPHO) ALL2008 protocol shows benefit Low pre-HCT MRD positivity, high-level 5-year OS.
-
ALL: potential dasatinib-MTX drug interaction identified SLCO1B1 allele variants may exacerbate reduced MTX clearance.
-
APL: study identifies risk factors for early death/relapse Age was the only independent predictor for early death.
-
Chronic lymphocytic leukaemia: NICE approves venetoclax with rituximab NICE had previously decided not to recommend the treatment based on evidence from the MURANO trial
-
Breast cancer survivors face excess risk for AML, MDS in French study Novel risks for ALL/LL and MM also identified.
-
AML/MDS: LEN/AZA regimen offers promise in post-transplant relapse Impressive responses, low-level toxicity.
-
CP-CML: expert recommendations for managing bosutinib AEs Special emphasis on diarrhea, nausea and vomiting, and myelosuppression.